Jan Steffen

Summary

Affiliation: Institute of Oncology
Country: Poland

Publications

  1. pmc Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal
    Magdalena Chechlinska
    Department of Immunology, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
    BMC Genomics 10:261. 2009
  2. ncbi [Advances in research on the molecular pathogenesis of the malignant tumours and implications for their early diagnosis and treatment]
    J Steffen
    Zaklad Immunologii, Centrum Onkologii Instytut im M Sklodowskiej Curie w Warszawie, Ul W K Roentgena 5, 02 781 Warszawa, Polska
    Med Wieku Rozwoj 4:11-25. 2000
  3. ncbi Increased risk of gastrointestinal lymphoma in carriers of the 657del5 NBS1 gene mutation
    Jan Steffen
    Department of Immunology, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 119:2970-3. 2006
  4. ncbi Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland
    Jan Steffen
    Department of Immunology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 119:472-5. 2006
  5. ncbi Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland
    Jan Steffen
    Department of Immunology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 111:67-71. 2004
  6. ncbi Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer
    Beata Bielinska
    Department of Molecular and Translational Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Fam Cancer 12:691-8. 2013
  7. ncbi Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor
    Janina Kaminska
    Department of Tumor Markers, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Poland
    Oncology 70:115-25. 2006
  8. ncbi Sera of lung cancer patients affect the release of Th1, Th2 and monocyte-derived cytokines, and the expression of IL-2Ralpha by normal, stimulated mononuclear cells
    Magdalena Chechlinska
    Department of Immunology, The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Cell Mol Biol Lett 9:69-81. 2004
  9. ncbi Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcomas, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    J Surg Oncol 84:151-9. 2003
  10. ncbi Spontaneously immortalized T lymphocytes from Nijmegen Breakage Syndrome patients display phenotypes typical for lymphoma cells
    Jan Konrad Siwicki
    Department of Immunology, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, 02 781 Warsaw, Roentgena 5, Poland
    Leuk Res 32:569-77. 2008

Detail Information

Publications12

  1. pmc Molecular signature of cell cycle exit induced in human T lymphoblasts by IL-2 withdrawal
    Magdalena Chechlinska
    Department of Immunology, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
    BMC Genomics 10:261. 2009
    ..We aimed to study gene expression profile of primary and immortalised IL-2-dependent human T cells forced to exit the cell cycle by growth factor withdrawal, before apoptosis could be evidenced...
  2. ncbi [Advances in research on the molecular pathogenesis of the malignant tumours and implications for their early diagnosis and treatment]
    J Steffen
    Zaklad Immunologii, Centrum Onkologii Instytut im M Sklodowskiej Curie w Warszawie, Ul W K Roentgena 5, 02 781 Warszawa, Polska
    Med Wieku Rozwoj 4:11-25. 2000
    ....
  3. ncbi Increased risk of gastrointestinal lymphoma in carriers of the 657del5 NBS1 gene mutation
    Jan Steffen
    Department of Immunology, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 119:2970-3. 2006
    ..52, 95% CI: 5.82-65.42, p = 0.0002). These findings imply that heterozygous NBS1 germline mutations may contribute significantly to the overall incidence of NHL, especially of the gastrointestinal tract, in Central Europe...
  4. ncbi Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland
    Jan Steffen
    Department of Immunology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 119:472-5. 2006
    ....
  5. ncbi Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland
    Jan Steffen
    Department of Immunology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 111:67-71. 2004
    ..Larger studies are needed to evaluate the impact of the high frequency of germline NBS1 mutations on the cancer burden in the Slav populations...
  6. ncbi Association of the BRCA1 promoter polymorphism rs11655505 with the risk of familial breast and/or ovarian cancer
    Beata Bielinska
    Department of Molecular and Translational Oncology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Fam Cancer 12:691-8. 2013
    ..001, OR = 3.7, 95% CI = 1.62-8.46). The presented evidence suggests a need to conduct larger studies on the association between genetic variations at the BRCA1 promoter and the breast cancer risk, according to maternal/paternal lineage...
  7. ncbi Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor
    Janina Kaminska
    Department of Tumor Markers, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Poland
    Oncology 70:115-25. 2006
    ..Cytokines are potential new serum markers, especially desirable for malignancies with poor prognosis like non-small cell lung cancer (NSCLC)...
  8. ncbi Sera of lung cancer patients affect the release of Th1, Th2 and monocyte-derived cytokines, and the expression of IL-2Ralpha by normal, stimulated mononuclear cells
    Magdalena Chechlinska
    Department of Immunology, The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Roentgena 5, 02 781 Warsaw, Poland
    Cell Mol Biol Lett 9:69-81. 2004
    ..We discuss a putative role of serum IL-10, IL-1ra, and soluble IL-2Ralpha in the effects observed...
  9. ncbi Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcomas, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    J Surg Oncol 84:151-9. 2003
    ....
  10. ncbi Spontaneously immortalized T lymphocytes from Nijmegen Breakage Syndrome patients display phenotypes typical for lymphoma cells
    Jan Konrad Siwicki
    Department of Immunology, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, 02 781 Warsaw, Roentgena 5, Poland
    Leuk Res 32:569-77. 2008
    ..These cell lines may be useful for the in vitro elucidation of mechanisms involved in the development of ALCL...
  11. ncbi Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis
    Piotr Rutkowski
    Department of Soft Tissue Bone Sarcomas, M Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    Int J Cancer 100:463-71. 2002
    ..Serum assays of IL-6, IL-8 and TNF RII before or after the treatment may be useful in establishing soft tissue sarcoma patients prognosis...
  12. doi The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland
    Maria Sromek
    Department of Endocrinology, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, W K Roentgen 5, 02 781 Warsaw, Poland
    Endocr Pathol 21:178-85. 2010
    ..The presence of this polymorphic change in MTC patients carrying, at the same time, the RET codon 634 mutation lowers the age of onset of MTC in this group...